Australian researchers spearhead paradigm shift in melanoma treatment

Australian researchers spearhead paradigm shift in melanoma treatment

20 September 2021

In what has been described as a paradigm shift in the treatment of melanoma, drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients to stop disease spread and save lives.

Promising results from an international multi-centre clinical trial, which included researchers and patients from Melanoma Institute Australia (MIA), were presented this weekend at the prestigious European Society for Medical Oncology (ESMO) Congress.

Results showed giving high-risk Stage II melanoma patients the same immunotherapy drugs approved for use in advanced melanoma patients, reduced the risk of their disease returning or death by 35%.

Study author Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, said the findings would result in a paradigm shift in treatment of early stage patients.

‘We are using drug therapy already proven to be life-saving for advanced melanoma patients, to stop the disease in its tracks in earlier stage patients,’ Professor Long said. ‘These exciting clinical trial results are strong evidence to support approval for this immunotherapy to become standard treatment for high-risk  Stage II patients in Australia.’

The clinical trial demonstrated that giving pembrolizumab (Keytruda™) after surgery to patients with Stage IIB or IIC melanoma (deemed at high risk of spread due to tumour thickness or ulceration) reduced the risk of the disease returning or death by 35% compared to placebo. At 12 months, only 9.5% of patients on pembrolizumab had their melanoma progress, compared to 16.9% in the placebo group.

In the last decade, the approval of immunotherapy for Stage III and IV melanoma patients has dramatically increased survival rates, with more than 50% of these patients now essentially cured.

However, there are no immunotherapy drugs currently approved for use in Stage II melanoma patients. They instead have to adopt a ‘watch-and-wait’ approach after surgery to see if their cancer will return or spread. Patients with thick Stage II melanoma also often undergo an invasive Sentinel Node Biopsy to check for disease spread, with drug therapy only available once their disease has spread to their lymph nodes (Stage III).

Fellow study author Professor Richard Scolyer AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, says the clinical trial results stand to transform how earlier stage disease is managed.

‘By giving this immunotherapy treatment at an earlier stage, we are proactively preventing melanoma spread,’ Professor Scolyer said.

Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. An estimated 1300 Australians are expected to die from melanoma this year.

Following these clinical trial results, it is hoped pembrolizumab will soon come before the Pharmaceutical Benefits Advisory Committee (PBAC) for approval for use in these patients in Australia.

‘This proactive approach to preventing disease spread represents a significant step forward in our mission of reaching zero deaths from melanoma,’ Professor Scolyer added.

___________________________________________________________________________

The full data set was presented at ESMO on Saturday 18 September 2021 at 11:05pm (AEST) by Associate Professor Jason Luke in a presentation entitled: “Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial”.
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Scolyer and Professor Long lead the Translational Research Group at the Charles Perkins Centre.
 

Media contact:

Jennifer Durante |media@melanoma.org.au | 0412 798 990

Two melanoma treatments approved for PBS listing
24 Dec 2019

Two melanoma treatments approved for PBS listing

Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.    

Immunotherapy: the decade's biggest health advance
23 Dec 2019

Immunotherapy: the decade's biggest health advance

An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.  

 

Boost to Melanoma Services in the Riverina
12 Dec 2019

Boost to Melanoma Services in the Riverina

Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.

Winner of the SunSafe Student Ambassador Program announced
11 Dec 2019

Winner of the SunSafe Student Ambassador Program announced

Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.

Community Fundraising November Wrap-Up
04 Dec 2019

Community Fundraising November Wrap-Up

It’s time again to say thank you to our amazing community fundraisers!

MIA & MPA Patient Information Evening videos now available
03 Dec 2019

MIA & MPA Patient Information Evening videos now available

Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.

MIA shines in poster session
22 Nov 2019

MIA shines in poster session

MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.

MIA Co-Medical Director opens SMR Congress in USA
21 Nov 2019

MIA Co-Medical Director opens SMR Congress in USA

Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.

Highly Cited Researchers List names MIA Co-Medical Directors
20 Nov 2019

Highly Cited Researchers List names MIA Co-Medical Directors

MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.

MPA and MIA collaboration
07 Nov 2019

MPA and MIA collaboration

Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.

Community Fundraising October Wrap-Up
04 Nov 2019

Community Fundraising October Wrap-Up

It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe